Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

ding the most common HCV genotype in the US and Europe, GT1.  

At the annual meeting of the American Association for the Study of Liver Diseases (AASLD), Professor Edward Gane of New Zealand presented results from ELECTRON demonstrating viral cure (sustained viral response, SVR) in 40 of 40 (100%) patients with HCV GT2 or GT3.  ELECTRON was designed to determine the minimum duration of interferon required to achieve SVR in combination with the nucleotide analog PSI-7977 and RBV.  All 40 subjects were treated with PSI-7977/RBV, but were randomized to receive one of four "interferon sparing" or interferon-free regimens: 4, 8, or 12 weekly interferon injections, or no interferon. The early antiviral responses were consistent across all four experimental treatment groups with all 40 subjects achieving "undetectable" HCV RNA by week 4.  Importantly, there were no treatment failures or discontinuations due to safety or viral resistance during the 12 weeks of therapy, problems that have limited the effectiveness of other direct-acting antivirals in development for HCV.  

Data from PROTON, the Phase 2 dose-ranging trial for PSI-7977, were presented at AASLD by Dr. Eric Lawitz.  Initial 12-week safety and on-treatment response rates had been presented in early 2011, with 98% of subjects achieving HCV below limit of detection (<LOD), and no safety or tolerability issues in either cohort receiving PSI-7977 at 200 mg or 400 mg QD with Peg-IFN/RBV for 12 weeks.  During the Peg-IFN/RBV dosing from week 13 to 24, three subjects in the 200 mg cohort experienced viral breakthrough and one additional subject experienced relapse within 4 weeks of completing the treatment, for a combined 88% SVR12 for the lower-dose of PSI-7977.  In contrast, no viral breakthrough was observed in the PSI-7977 400 mg QD cohort, and only one relapse, for an intent to treat (ITT) SVR12 of 91% (43 of 47). Of the 44 subjects who received at least 8 we
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013 Oven Industries announces the new ... potentiometers or via a PC through the TTL level ... one half inches square can deliver up to 15 ... low noise solid state relay. Operator safety is achieved ... communication port and sensor input. Specifications: Input Voltage ...
(Date:5/22/2013)... MA (PRWEB) May 22, 2013 ... in Alexandria, VA for the Oak Ridge ... which will take place at the Hilton Alexandria ... Biodetection Technologies 2013 conference on June ... Already Participating: , AdSave, American Elements, Applied Research ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 iLuv Creative ... of accessories for the mobile lifestyle, announces they are ... protect, and manage multiple iPad devices efficiently. Winner of ... the 2012 Good Design award, MultiCharger-X is revolutionizing the ... wherever it is deployed. , MultiCharger-X (iAD910) ...
(Date:5/22/2013)... Cambridge Semantics was one of just ... Day” on Capitol Hill, hosted by The Data ... others to showcase how innovative data management applications can address ... (DATA Act). , Originally introduced in 2011 by Committee ... Mark Warner (D-VA ), the DATA Act is ...
Breaking Biology Technology:New AC Temperature Controller Announced by Oven Industries 2Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 2Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 3Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 4Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 5iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2
... Enterprise ... the bank. , ... 1, 2009 -- PacsDrive, LLC. ( www.pacsdrive.com ), a medical imaging software company, ... small and medium sized health care providers to securely archive medical imaging in compliance with ...
... ... migrate their Microsoft Dynamics SL clients (including project accounting clients) to Synergy Business Solutions ... ... it has acquired the Microsoft Dynamics SL practice of Congruent Software, a Bellevue, WA ...
... , SAN DIEGO, Dec. 1 ... it will present at the LD MICRO Conference on Thursday, December ... Los Angeles. Aethlon Medical,s Chairman and CEO, James A. Joyce, will ... company,s clinical progress for its lead product, the Hemopurifier®, a first-in-class ...
Cached Biology Technology:PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3Aethlon Medical to Present at LD MICRO Conference on December 3, 2009 2
(Date:5/22/2013)... May 22, 2013 U.S. Forest Service scientists are ... with funding from the TKF Foundation, will examine how ... and individuals recover from tragedy. , The TKF Foundation ... six projects selected for grant funding. In addition to ... spaces in recovery and resiliency, the 3-year, $585,000 grant ...
(Date:5/22/2013)... Lung Screening Trial (NLST) investigators also conclude that ... with low-dose computed tomography (LDCT) versus chest X-ray ... paper is achievable at experienced screening centers in ... information to share with their patients about the ... following today,s publication in the New England ...
(Date:5/22/2013)... durability in fuel cell powered buses, including a ... between electrode degradation processes and bus membrane durability. ... electrode degradation stressors in the operating cycle of ... findings of the study, led by SFU graduate ... long-term study at Burnaby-based Ballard Power Systems and ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Tests lead to doubling of fuel cell life 2
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced ... of the results of two pivotal animal efficacy ... human monoclonal antibody drug raxibacumab (ABthrax), as well as ... use of raxibacumab in the event of life-threatening inhalation ...
... article appearing in Environmental Health Perspectives ... associate for the Project on Emerging Nanotechnologies (PEN), ... cleanup. It provides an overview of current ... and safety implications; and possible future directions for ...
... Van Andel Research Institute (VARI) investigators ... therapeutic target in the treatment of the most aggressive ... have few treatment options. "Breast cancer mortality rates ... to traditional treatments tend to be more aggressive and ...
Cached Biology News:Data published in the New England Journal of Medicine support use of raxibacumab (ABthrax) for the treatment of inhalation anthrax 2Contaminated site remediation: Are nanomaterials the answer? 2Possible drug target found for one of the most aggressive breast cancers 2
... Sigmas FLAG Immunoprecipitation kit allows a ... of an active FLAG-tagged protein. The ... gel, which is a highly specific ... resin. The use of affinity resin ...
... GX-1000 3-D Shaker , ,Product Information ... of the GyroTwister GX-1000 is extremely efficient, ... general mixing as well as staining gels, ... continuously adjustable across a broad range. A ...
... Chromatography Data System (CDS) now provides ... chromatography data processing and reporting for ... LC. The companys innovative HPLC instrument ... benefits of Thermo Scientific Hypersil GOLD ...
... NanoMate 100 robotic system and disposable ESI ... of the capabilities of electrospray mass spectrometers ... with MS allows users to either speed ... and peptide mapping applications, or long acquisition ...
Biology Products: